A Phase I Study of TPI 287 - Temozolomide Combination in Melanoma
NCT01067066
·
clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
21
Enrollment
OTHER
Sponsor class
Stopped
Phase I/II study halted as Phase I, Low Response Rate
Conditions
Melanoma
Interventions
DRUG:
TPI 287
DRUG:
Temodar (Temozolomide)
Sponsor
M.D. Anderson Cancer Center
Collaborators
[object Object]